Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of rituximab induction and living donor kidney transplantation on immune regulation and viral control – prospective pilot study
2009-012198-36Phase 2Completed
- Sponsor
- Universitätsklinikum Gießen und Marburg
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in end-stage kidney disease (ESKD) and Kidney allograft status (RTx), sponsored by Universitätsklinikum Gießen und Marburg. Primary endpoints: Immunological parameters relevant to graft outcome, Patient survival and 1 more. Started Oct 2009; status: completed.
02
Drugs
rituximab
03
Conditions
end-stage kidney disease (ESKD)Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2009-012198-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012198-36.